Clinical bottom line
Refractory Helicobacter pylori infection, defined as failure to eradicate the bacterium after two or more treatment attempts, remains a challenging clinical problem largely driven by increasing antimicrobial resistance. Recent advances emphasize precision eradication strategies guided by susceptibility testing, novel pharmacotherapeutics including potassium-competitive acid blockers (P-CABs), and optimized combination regimens. While these approaches show promise in improving eradication rates, evidence is still emerging and requires integration with local resistance patterns and patient-specific factors. Clinicians should consider tailored therapy incorporating susceptibility data where available and remain vigilant for evolving resistance trends.
What the evidence shows
Antimicrobial resistance is the principal driver of refractory H. pylori infection, with clarithromycin, metronidazole, and levofloxacin resistance rates rising globally (Sun et al., 2026; Saha et al., 2026). Empiric retreatment regimens often fail without susceptibility guidance, underscoring the need for precision medicine approaches. Recent studies highlight the utility of culture or molecular-based susceptibility testing to inform second- and third-line therapies, which significantly improve eradication success compared to empiric regimens (Sun et al., 2026).
Pharmacotherapeutic advances include the introduction of potassium-competitive acid blockers (P-CABs) such as vonoprazan, which provide more potent and sustained acid suppression than proton pump inhibitors (PPIs). This enhanced acid control improves antibiotic stability and efficacy, leading to higher eradication rates in refractory cases (Davis et al., 2025; Lanas-Gimeno et al., 2026). Clinical trials demonstrate that P-CAB-based triple or quadruple regimens outperform traditional PPI-based therapies, particularly in regions with high clarithromycin resistance (Sun et al., 2026).
Optimized combination therapies incorporating bismuth, tetracycline, and rifabutin have also shown efficacy in refractory infections. Bismuth quadruple therapy remains a cornerstone for rescue treatment, with modifications tailored to resistance profiles (Saha et al., 2026). Rifabutin-containing regimens are emerging as effective salvage options, though concerns about cost, availability, and potential adverse effects warrant cautious use (Sun et al., 2026).
Adjunctive strategies such as extending treatment duration to 14 days and ensuring patient adherence are critical to maximizing eradication success (Borao Laguna et al., 2023). Novel agents and combination regimens are under investigation but require further validation before routine clinical adoption.
Caveats and uncertainty
Despite advances, several uncertainties remain. Susceptibility testing is not universally available or standardized, limiting its widespread implementation. Molecular assays may not detect all resistance mechanisms, and culture-based methods are labor-intensive and time-consuming (Sun et al., 2026). Regional variations in resistance patterns necessitate local epidemiological data to guide therapy, which may be lacking in many settings.
Long-term safety data for newer agents like P-CABs and rifabutin in diverse populations are limited, and potential drug interactions require careful consideration (Davis et al., 2025). The optimal sequencing of therapies after multiple failures is not well established, and evidence is often derived from small or observational studies (Saha et al., 2026).
Patient factors such as compliance, reinfection risk, and underlying gastric pathology also influence outcomes but are difficult to control in clinical practice. Finally, the impact of emerging resistance to novel agents remains to be seen, underscoring the need for ongoing surveillance and research.
How this may change practice
Clinicians managing refractory H. pylori infection should prioritize obtaining susceptibility data when feasible to guide tailored therapy. Incorporating P-CABs into eradication regimens may improve outcomes, particularly in regions with high resistance to PPIs or clarithromycin. Bismuth quadruple therapy remains a key rescue option, with rifabutin-based regimens reserved for multiply refractory cases.
Extending treatment duration to 14 days and reinforcing adherence strategies are practical measures to enhance eradication success. Awareness of local resistance patterns and emerging pharmacotherapies will enable more informed regimen selection. Multidisciplinary collaboration with microbiology laboratories and gastroenterology specialists can facilitate precision management.
Ongoing research and surveillance are essential to refine treatment algorithms and address gaps in evidence. Clinicians should remain cautious and individualize therapy, balancing efficacy, safety, and patient preferences.